Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis

Abstract

Background:

Fingolimod modulates sphingosine-1-phosphate receptors that are also found in cardiovascular tissue.

Objective:

To investigate the effects of fingolimod on cardiac autonomic regulation prospectively.

Methods:

Twenty-seven relapsing–remitting multiple sclerosis patients underwent 24-hour electrocardiogram recording before, at the first day of fingolimod treatment (1d) and after three months of continuous dosing (3mo). The time interval between two consecutive R-peaks (RR-interval) was measured. Cardiac autonomic regulation was assessed by the various parameters of heart rate variability. Parasympathetic stimulation prolongs the RR-interval and increases heart rate variability while the effects of sympathetic stimulation are mainly the opposite. The low frequency/high frequency ratio reflects sympathovagal balance.

Results:

From baseline to 1d, a prolongation of the RR-interval (P<0.001), an increase in the values of various heart rate variability parameters (P<0.05 to P<0.001) and a decrease in the low frequency/high frequency ratio (P<0.05) were demonstrated. At 3mo, although the RR-interval remained longer (P<0.01), the values of various heart rate variability parameters were lower (P<0.01 to P<0.001) as compared to baseline. At 3mo, the low frequency/high frequency ratio (P<0.05) was higher in men than in women although no such difference was found at baseline or at 1d.

Conclusions:

After an initial increase in parasympathetic regulation, continuous fingolimod dosing shifts cardiac autonomic regulation towards sympathetic predominance, especially in men. Careful follow-up of fingolimod-treated relapsing–remitting multiple sclerosis patients is warranted as sympathetic predominance associates generally with impaired outcome.

ClinicalTrials.cov: NCT01704183

Keywords

Cardiac autonomic regulation fingolimod heart rate variability multiple sclerosis

Get full access to this article

View all access options for this article.

References

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Chun

Hartung

. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91–101.

Mandala

Hajdu

Bergstrom

. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346–349.

Matloubian

Cinamon

. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355–360.

Mehling

Johnson

Antel

. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011; 76: S20–S27.

Brinkmann

. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007; 115: 84–105.

Brinkmann

Billich

Baumruker

. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883–897.

Mizugishi

Yamashita

Olivera

. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005; 25: 11113–11121.

10.

Camm

Hla

Bakshi

. Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications. Am Heart J 2014; 168: 632–634.

11.

Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043–1065.

12.

Hartikainen

Malik

Staunton

. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996; 28: 296–304.

13.

Kleiger

Miller

Bigger

JTJ

. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256–262.

14.

Tsuji

Larson

Venditti

. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996; 94: 2850–2855.

15.

Simula

Laitinen

. Effects of three months fingolimod therapy on heart rate. J Neuroimmune Pharmacol 2015; doi 10.1007/s11481-015-9619-8

16.

Monfredi

Lyashkov

Johnsen

. Biophysical characterization of the underappreciated and important relationship between heart rate variability and heart rate. Hypertension 2014; 64: 1334–1343.

17.

Pomeranz

Macaulay

RJB

Caudill

. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985; 248: H151–H153.

18.

Akselrod

Gordon

Ubel

. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat to beat cardiovascular control. Science 1981; 213: 220–222.

19.

Koyrakh

Roman

Brinkmann

. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529–536.

20.

Rossi

Rocchi

Struder

. The autonomic balance predicts cardiac responses after the first dose of fingolimod. Mult Scler 2015; 21: 206–216.

21.

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 16: 545–556.

22.

Laroni

Brogi

Morra

. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014; 14: 65. doi: 10.1186/1471-2377-14-65

23.

Murakami

Takasugi

Ohnuma

. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol 2010; 77: 704–713.

24.

Malik

Camm

. Components of heart rate variability – what they really mean and what we really measure. Am J Cardiol 1993; 72: 821–822.

25.

Gold

Comi

Palace

. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 2014; 261: 267–276.

26.

FDA, US Food and Drug Administration. Gilenya (fingolimod) capsules prescribing information, May 2015. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm266123.htm (accessed 24 August 2015).

27.

Huikuri

Pikkujämsä

Airaksinen

. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996; 94: 122–125.

28.

Umetani

Singer

McCraty

. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol 1998; 31: 593–601.